AEON Biopharma, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

FY: Dec 31 2024

Q: Mar 31 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

FY: Dec 31 2023

Q: Jun 30 2024

FY: Dec 31 2023

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

Q: Mar 31 2023

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Other Events

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Results of Operations and Financial Condition

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Unregistered Sales of Equity Securities

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Prospectus Supplement with Pricing Information

No description available

Notice of Effectiveness

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Required Information in Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

LYNCH TIMOTHY P

LYNCH TIMOTHY P

LYNCH TIMOTHY P

Stonepine Capital Management, LLC

FISCHER JOST

Thunen Shelley B

PALMISANO ROBERT J

Carter Eric G

Forth Marc

Bencich John

Bencich John

Oh Chad

Sy Jennifer

Wilson Alexander Blair

Bancroft Robert E.

Daewoong Co., Ltd

Daewoong Co., Ltd

Daewoong Co., Ltd

Alta Partners LLC

Alta Partners LLC

Draft registration statement (confidential submission)

Annual Report Scanned (Paper)

Letter from the SEC

Correspondence with the SEC

Annual Report Scanned (Paper)

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Annual Report Scanned (Paper) (amendment)

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC